Arcus Biosciences at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
Arcus Biosciences brings 3 presentations to ENA 2026 in Barcelona. Its posters centre on the HIF-2α inhibitor casdatifan, from an activity signature that points to its potential in HCC to combinations with checkpoint receptor modulation. It also shows that targeting AXL overcomes inherent resistance to RAS-targeting therapies.
| Organization | ENA 2026 Attendance |
|---|---|
Arcus Biosciences Hayward, CA | |
Develops cancer medicines including the HIF-2 alpha inhibitor casdatifan and immunotherapy combinations. | Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm |
Instantly find 20 buyers from Arcus Biosciences
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction